Scientific publications

Ki67: a time-varying biomarker of risk of breast cancer in atypical hyperplasia

Marta Santisteban (1), Carol Reynolds (2), Emily G. Barr Fritcher (2), Marlene H. Frost (3), Robert A. Vierkant (4), Stephanie S. Anderson (4), Amy C. Degnim (5), Daniel W. Visscher (6), V. Shane Pankratz (4) and Lynn C. Hartmann (3)
(1) Department of Oncology, Clinica Universitaia de Navarra, Navarra, Spain
(2) Department of Laboratory Medicine and Pathology, Mayo Clinic Cancer Center, Mayo Graduate School of Medical Education, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
(3) Division of Medical Oncology, Department of Oncology, Mayo Clinic Cancer Center, Mayo Graduate School of Medical Education, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55905, USA
(4) Department of Health Sciences Research?Biostatistics, Mayo Clinic Cancer Center, Mayo Graduate School of Medical Education, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
(5) Department of General Surgery, Mayo Clinic Cancer Center, Mayo Graduate School of Medical Education, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
(6) Department of Pathology, University of Michigan, Ann Arbor, MI, USA

Magazine: Breast Cancer Research and Treatment

Date: Sep 23, 2009

Breast Cancer Area Medical Oncology

Uncontrolled proliferation is a defining feature of the malignant phenotype. Ki67 is a marker for proliferating cells and is overexpressed in many breast cancers. Atypical hyperplasia is a premalignant lesion of the breast (relative risk ~ 4.0).

Here, we asked if Ki67 expression could stratify risk in women with atypia. Ki67 expression was assessed immunohistochemically by digital image analysis in archival sections from 192 women with atypia diagnosed at the Mayo Clinic 1/1/67-12/31/91. Risk factor and follow-up data were obtained via study questionnaire and medical records. Observed breast cancer events were compared to population expected rates (Iowa SEER) using standardized incidence ratios (SIRs). We examined two endpoints: risk of breast cancer within 10 years and after 10 years of atypia biopsy. Thirty-two (16.7%) of the 192 women developed breast cancer over a median of 14.6 years. Thirty percent (58) of the atypias had >/=2% cells staining for Ki67. In these women, the risk of breast cancer within 10 years after atypia was increased (SIR 4.42 [2.21-8.84]) but not in those with <2% staining.

Specifically, the cumulative incidence for breast cancer at 10 years was 14% in the high Ki67 vs. 3% in the low Ki67 group. Conversely, after 10 years, risk in the low Ki67 group rose significantly (SIR 5.69 [3.63-8.92]) vs. no further increased risk in the high Ki67 group (SIR 0.78 [0.11-5.55]). Ki67 appears to be a time-varying biomarker of risk of breast cancer in women with atypical hyperplasia.

CITATION  Breast Cancer Res Treat. 2010 Jun;121(2):431-7

you maybe interested

WHAT TECHNOLOGY
DO WE USE?

The Clínica is the greater private hospital with technological equipment of Spain, all in a single center.

Imagen de un PET, tecnología de vanguardia en la Clínica Universidad de Navarra

OUR
PROFESSIONALS

The professionals of the Clínica perform continuous research and training, always to the benefit of the patient.

Imagen profesionales de la Clínica Universidad de Navarra

WHY CHOOSE
THE CLINICA?

Learn why we are different from other healthcare centers. Quality, speed, comfort and results.

Imagen del edificio de la Clínica Universidad de Navarra